Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Free Cash Flow (2021 - 2025)

Kiniksa Pharmaceuticals International's Free Cash Flow history spans 5 years, with the latest figure at $54.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 192.85% year-over-year to $54.7 million; the TTM value through Dec 2025 reached $137.9 million, up 442.66%, while the annual FY2025 figure was $137.9 million, 442.66% up from the prior year.
  • Free Cash Flow reached $54.7 million in Q4 2025 per KNSA's latest filing, up from $33.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $62.0 million in Q3 2022 to a low of -$40.2 million in Q1 2021.
  • Average Free Cash Flow over 5 years is $2.8 million, with a median of $766000.0 recorded in 2024.
  • Peak YoY movement for Free Cash Flow: tumbled 113.87% in 2024, then soared 1502.72% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$19.1 million in 2021, then soared by 39.67% to -$11.5 million in 2022, then soared by 137.64% to $4.3 million in 2023, then skyrocketed by 330.24% to $18.7 million in 2024, then soared by 192.85% to $54.7 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Free Cash Flow are $54.7 million (Q4 2025), $33.0 million (Q3 2025), and $27.9 million (Q2 2025).